[PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects]
Standard
[PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects] : Urologe A. / Rauscher, I.; Eiber, M.; Jilg, C. A.; Gschwend, J. E.; Maurer, T.
In: UROLOGE, Vol. 56, No. 1, 2017, p. 18-23.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects]
T2 - Urologe A
AU - Rauscher, I.
AU - Eiber, M.
AU - Jilg, C. A.
AU - Gschwend, J. E.
AU - Maurer, T.
N1 - 1433-0563 Rauscher, I Eiber, M Jilg, C A Gschwend, J E Maurer, T Journal Article Review Germany Urologe A. 2017 Jan;56(1):18-23. doi: 10.1007/s00120-016-0275-2.
PY - 2017
Y1 - 2017
N2 - Recently, PSMA-radioguided surgery (PSMA-RGS) was introduced for targeted resection of localized prostate cancer recurrence. Prerequisite for preoperative patient selection and localization of tumor recurrence is a positive (68)Ga-HBED-CC PSMA positron emission tomography (PET) scan with preferably only singular soft tissue or lymph node recurrence. After injection of In-PSMA I&T or Tc-PSMA-I&S single photon emission computer tomography (SPECT)/computer tomography (CT) examination is performed in every patient to verify radiotracer uptake in tumor lesions. In a preliminary study, (111)In-PSMA I&T SPECT/CT could detect about half of the (68)Ga-HBED-CC PSMA PET-positive lesions, while nearly all PET-positive lesions could be detected using PSMA-RGS and also five additional lesions compared to (68)Ga-HBED-CC-PSMA PET. Follow-up data from 55 patients show a PSA reduction >50% and >90% in 44 (80%) and 29 (53%) patients, respectively. In 34 (62%) patients, a PSA drop to
AB - Recently, PSMA-radioguided surgery (PSMA-RGS) was introduced for targeted resection of localized prostate cancer recurrence. Prerequisite for preoperative patient selection and localization of tumor recurrence is a positive (68)Ga-HBED-CC PSMA positron emission tomography (PET) scan with preferably only singular soft tissue or lymph node recurrence. After injection of In-PSMA I&T or Tc-PSMA-I&S single photon emission computer tomography (SPECT)/computer tomography (CT) examination is performed in every patient to verify radiotracer uptake in tumor lesions. In a preliminary study, (111)In-PSMA I&T SPECT/CT could detect about half of the (68)Ga-HBED-CC PSMA PET-positive lesions, while nearly all PET-positive lesions could be detected using PSMA-RGS and also five additional lesions compared to (68)Ga-HBED-CC-PSMA PET. Follow-up data from 55 patients show a PSA reduction >50% and >90% in 44 (80%) and 29 (53%) patients, respectively. In 34 (62%) patients, a PSA drop to
KW - Edetic Acid/analogs & derivatives Evidence-Based Medicine Forecasting Humans Male Neoplasm Recurrence, Local/diagnostic imaging/radiotherapy Oligopeptides Organometallic Compounds Positron-Emission Tomography/trends Prostatectomy/methods/trends Prostatic
U2 - 10.1007/s00120-016-0275-2
DO - 10.1007/s00120-016-0275-2
M3 - SCORING: Zeitschriftenaufsatz
VL - 56
SP - 18
EP - 23
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 1
ER -
